Navigation Links
Dermata Therapeutics, LLC and Villani, Inc. Announce a Global License Agreement for a Natural Sponge Product for Skin Diseases

SAN DIEGO, April 13, 2017 /PRNewswire/ -- Dermata Therapeutics, LLC and Villani, Inc., today announced they have entered into an exclusive global license agreement for Villani's natural sponge product, to be developed by Dermata as a potential treatment for a variety of skin diseases.  Dermata will have the exclusive worldwide rights to develop and commercialize Villani's patented sponge-based product, with the first target being the treatment of moderate to severe acne vulgaris.  Under the terms of the license agreement, Villani will receive milestone and royalty payments.   

"We are pleased to announce this collaboration with Villani and believe it further enhances Dermata's mission to make major advancements in the treatment of serious skin diseases," states Gerald Proehl, President and CEO of Dermata.  "After many years of research, Dr. Villani has developed a product to harness the therapeutic effects of a natural sponge product that has the potential to address the needs of patients with moderate to severe acne.  While prescription acne products have been available for many years, patients continue to suffer from the emotional and physical effects of living with the disease.  We believe that developing a natural alternative to currently available prescription products will represent a major advancement in the treatment of acne."  

"I am very excited to begin working with the Dermata team to bring this potentially significant breakthrough to patients living with moderate to severe acne because I know firsthand how patients feel living with acne," said Maria Villani, M.D., CEO and founder of Villani, Inc. "This product has been years in the making, filled with hours of research.  I look forward to collaborating with the Dermata team to further advance development of my sponge product, hopefully bringing the first natural prescription drug product to market for moderate to severe acne sufferers."

This sponge product was discovered by Dr. Villani through examining many fresh water sponge species until she located a specific variant with a unique chemical structure.  Based on Dr. Villani's research and testing, to ensure the same unique chemical structure with each harvest, the sponge must be harvested under very strict environmental conditions and processed under a strict protocol.  The result of these strict requirements is a consistent chemical structure that is reproducible year to year, which is critical to developing this first ever sponge-derived product as a prescription. 

About Dermata: Dermata is a development-stage biotechnology company focused on making major advancements in the treatment of serious diseases treated by dermatologists. Dermata has an experienced team who are currently focused on progressing four programs for the treatment of acne rosacea, atopic dermatitis, acne vulgaris and ocular rosacea.  To learn more about Dermata and its pipeline of products, please visit

About Villani: Villani is a research-based dermatology company developing natural sponge-based products for both cosmetic and pharmaceutical use.  Maria Villani has spent over 18 years investigating the effects naturally produced by marine sponges, which led to her research and development of this product.  For more information, please visit

CONTACT: Dermata Contact Sean Proehl Public Relations 858.223.0882sproehl@dermatarx.comVillani ContactMaria VillaniPublic


To view the original version on PR Newswire, visit:

SOURCE Dermata Therapeutics, LLC
Copyright©2017 PR Newswire.
All rights reserved

Related medicine technology :

1. Dermata Therapeutics, LLC Announces Initiation of Treatment in a Phase 2 Acne Rosacea Clinical Study
2. Signum Dermalogix Out-Licenses SIG990 to Dermata Therapeutics for Topical Treatment of Rosacea
3. KNOW Bio Respiratory Has New Name, Novoclem Therapeutics, New Antimicrobial Drug Candidate for Lung, Respiratory Infections
4. Research Reports Initiation on Biotech Stocks -- Epizyme, Sierra Oncology, Five Prime Therapeutics, and AveXis
5. Non-Opioid Drug Development Firm, CerSci Therapeutics, Announces Appointment of Pharma Leaders Pat Confalone and Perry Molinoff to the Board of Directors
6. Research Reports Initiation on Biotech Stocks -- Sarepta Therapeutics, Galena Biopharma, Anthera Pharma, and Clovis Oncology
7. Generic Drugs Stocks on Investors Radar -- Diplomat Pharma, Momenta Pharma, Agile Therapeutics, and Sophiris Bio
8. Biotech Stocks on Investors Radar -- Merrimack Pharma, Amicus Therapeutics, CEL-SCI, and Cempra
9. Biotech Stocks Under Scanner -- Rexahn Pharma, Northwest Biotherapeutics, Celldex Therapeutics, and Vertex Pharma
10. Lung Therapeutics, Inc. Doses First Patient in Phase 1 Clinical Trial of LTI-01 in Australia and New Zealand
11. Research Reports Coverage on Generic Drugs Stocks -- Galectin Therapeutics, Catalyst Pharma, Innocoll, and Tetraphase Pharma
Post Your Comments:
(Date:3/30/2021)... ... March 29, 2021 , ... The University of Texas Health Science Center ... San Antonio Multispecialty and Research Hospital, a destination center for research and treatment of ... In a nod to the COVID-19 pandemic, the ceremony was held virtually. , William ...
(Date:3/30/2021)... ... March 29, 2021 , ... Iora Health ... primary care, has partnered with Devoted Health , one of the fastest-growing ... across Maricopa County and provides seniors with the highest-quality care and experience possible, ...
(Date:3/30/2021)... CITY (PRWEB) , ... March 29, 2021 , ... ... has joined the Vaccine Credential Initiative (VCI), a group bringing together leading health ... record of vaccination status, based on open, interoperable standards. By joining the VCI ...
Breaking Medicine Technology:
(Date:3/30/2021)... , ... March 29, 2021 , ... ... the 21st Century , A Virtual Workshop Presented by WCG FDAnews and Cerulean ... 4:30 pm EDT, , Are one’s SOPs written for the ...
(Date:3/30/2021)... ... March 29, 2021 , ... According to data released ... reproductive age (13-44) in need of publicly funded contraception live in counties impacted by ... Colorado’s 64 counties have lost some of their Title X resources. , The ...
(Date:3/30/2021)... ... March 29, 2021 , ... Health Literacy Innovations (HLI), a ... confusion due to low health literacy today announces a new partnership with the ... work with ACAP’s member Safety Net Health Plans, those that provide comprehensive health ...
(Date:3/30/2021)... ... ... Dr. Colin Campbell is proud to announce the 1 year anniversary in their new state ... internal medicine and is a primary care specialist who has been practicing for 23 years. ... keep South Jersey healthy one patient at a time. , “Over the past year, Dr. ...
(Date:3/30/2021)... ... March 30, 2021 , ... The COVID-19 ... and survivors; their families; and their caregivers. Crossroads4Hope is addressing the needs of ... emotional support system, MyGo2Support, which meets needs of people impacted by cancer, no ...
Breaking Medicine News(10 mins):